Full-Time

Vice President

Toxicology

Confirmed live in the last 24 hours

Orbital Therapeutics

Orbital Therapeutics

51-200 employees

Develops RNA-based medicines and therapies

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Ph.D. with 12+ years of scientific experience OR Master's degree with 13+ years of scientific experience. Candidates with DVM highly preferred.
  • Bachelor's degree with 15 + years of scientific experience in preclinical toxicology will also be considered.
  • 3+ years of experience with LNP, RNA, and gene therapies highly preferred.
  • Ability to develop and deliver clear and concise presentations for both internal and external meetings.
  • In-depth understanding of all aspects of nonclinical safety and experience with regulatory filings.
  • Extensive knowledge of relevant FDA and EMEA regulations and processes.
  • Demonstrated proven experience in working with CROs for protocol design and study execution.
  • Ability to operate effectively within an innovative and science-driven company environment; delivery-oriented, able to inspire others, driven and hands-on with unquestionable integrity and the highest ethical standards.
Responsibilities
  • Serving as the function head, this role will lead the nonclinical safety strategy and execution for programs across discovery, nonclinical, and clinical stages.
  • Oversee nonclinical safety related activities from discovery through regulatory filings and to commercialization for both our in-vivo development programs.
  • Develop and oversee the execution of phase appropriate nonclinical safety strategies along with integrated project plans including milestones, timelines, and budgets.
  • Provide strategic contribution as the subject matter expert for GLP, non-GLP safety assessments, off-target risk assessment, and safety pharmacology studies supporting development and platform programs.
  • Provide toxicology support for regulatory submissions and interactions with health authorities, including the authoring of nonclinical safety sections of US and international regulatory applications and help resolve nonclinical safety queries.
  • Drive and be accountable for delivery of high-quality safety reports to ensure clinical plans and regulatory filing submissions in multiple markets.
  • Oversee in vivo pharmacology team to allow the execution of animal studies.
  • Serve at the toxicology and/or nonclinical representative in cross-functional meetings both internally and externally.

Orbital Therapeutics focuses on developing RNA-based medicines, specifically targeting areas like vaccines, immunomodulation, and protein replacement. The company utilizes RNA technology along with advanced delivery methods and data science to create a platform for a wide range of therapeutic applications. Unlike many competitors, Orbital Therapeutics does not work with small interfering RNA, which sets it apart in the RNA medicine space. The goal is to enhance global health by harnessing RNA medicines to treat diseases in innovative ways that were not possible before. Revenue is generated through the sale of these medicines to healthcare providers who treat patients with various conditions.

Company Stage

Series A

Total Funding

$262.6M

Headquarters

San Francisco, California

Founded

2022

Growth & Insights
Headcount

6 month growth

13%

1 year growth

11%

2 year growth

235%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $270 million in Series A financing provides substantial capital to advance their RNA-based therapeutic platform.
  • The company's focus on next-generation vaccines, immunomodulation, and protein replacement positions it at the forefront of innovative treatments for various diseases.
  • Strategic partnerships, such as with Beam Therapeutics, enhance Orbital's capabilities in RNA and delivery technologies, broadening their therapeutic applications.

What critics are saying

  • The highly competitive field of RNA-based medicines requires continuous innovation to maintain a leading position.
  • The complexity of developing and commercializing RNA-based therapies could lead to longer timelines and higher costs.

What makes Orbital Therapeutics unique

  • Orbital Therapeutics focuses exclusively on RNA-based medicines, excluding small interfering RNA, which sets it apart from other genetic medicine companies.
  • The company leverages a unique combination of RNA technology, delivery methods, data science, and automation to create a versatile platform for developing a broad range of medicines.
  • The leadership team, including Dr. Giuseppe Ciaramella, brings extensive experience in drug discovery and biotherapeutics, providing a strategic advantage in the competitive landscape.

Help us improve and share your feedback! Did you find this helpful?